Artiva Biotherapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Artiva Biotherapeutics develops off-the-shelf allogeneic natural killer (NK) cell therapies for cancer; lead program AB-101 targets B-cell malignancies and autoimmune disease; raised over $230M including a $150M Series C;
About
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company founded in 2019 with a mission to develop off-the-shelf, allogeneic natural killer (NK) cell therapies that can transform cancer treatment. NK cells are innate immune cells that can identify and kill cancer cells without requiring the patient-specific manufacturing that makes autologous CAR-T therapies so expensive and logistically complex. Artiva's allogeneic (donor-derived) approach enables manufacturing at scale from healthy donors, producing standardized cell therapy products that can be stored and shipped like conventional drugs.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.